Healthpeak Properties, Inc. · NYSE:DOC

Healthpeak Properties — Q3 2020 Earnings Presentation

58 slides from Healthpeak Properties's earnings presentation, Nov 2, 2020

  1. Slide 1: Healthpeak Properties Supplemental Report

    <EK<EE@8C)+ <M<CFGD<EKI<E;<I@E> &3E:H;>>7 ,& 3D@;@9E*7>73E7 3@6+GBB>7?7@F3>*7BADF 7777777777777777777777777777777777777777777777777777777777777777777 ,:;D6)G3DF7D

  2. Slide 2: Contents

    0(!+" FEK<EKJ !8IE@E>J.<C<8J< FEJFC@;8K<;"@E8E:@8C/K8K<D<EKJ +M<IM@<N ,FIK=FC@F/LDD8IP ,IFG<IKPFLEK.<:FE:@C@8K@FEJ 8G@K8C@Q8K@FE8E;%E;<9K<;E<JJ %EM<JKD<EK/LDD8IP <M<CFGD<EKJ8E;.<;<M<CFGD<EKJ 8G@K8C!OG<E;@KLI<J ,FIK=FC@F @M<IJ@=@:8K@FE !OG@I8K@FEJ )8KLI@K@<J8E;,LI:?8J<+GK@FEJ 0I@GC< E<K)8JK<I(<8J<,IF

  3. Slide 3: Earnings Release Highlights

    73>F:B73=(DAB7DF;7E,%*7BADFE,:;D6)G3DF7D*7EG>FE %.2%*! 8C@= *FM<D9<I $<8CK?G<8B,IFG<IK@<J %E:*5/!,!' KF;8P8EEFLE:<;I<JLCKJ=FIK?<K?@I;HL8IK<I<E;<;/<GK<D9<I "FIK?<HL8IK<I N<><E<I8K<;8E<KCFJJF= G<IJ?8I< *.!%0""+F=G<IJ?8I< ""+8J;ALJK<;F=G<IJ?8I<8E;9C<E;<;0FK8C/8D< /KFI<,FIK=FC@F8J?*+%I<JLCKJF= , !*)-*,*

  4. Slide 4: Reconciliations and Net Income Summary

    ,:D77%A@F:E@676 ,:D77%A@F:E@676 +7BF7?47D +7BF7?47D & !&" &&&! ?AG@F (7DN+:3D7 ?AG@F (7DN+:3D7 *<K@E:FD<CFJJ ;@CLK<; *.!%0""+ ;@CLK<; ""+8J;ALJK<; ;@CLK<; ""+ ;@CLK<; *.!%0""+ ""+8J;ALJK<; ""+ /8D< /KFI<8J?*+% *<K <9K8E;;ALJK<;!%0 I<8I<JLGGC<D<EK8CEFE #,=@E8E:@8CD<8JLI<JK?8KN<9<C@<M<8I<LJ<=LC@E<M8CL

  5. Slide 5: Acquisitions

    )-!+!,!'&+ %E+:KF9<I <O<:LK<;8;<=@E@K@M<8>I<<D<EKKF8:HL@I<8D9I@;>< @J:FM<IP,8IB 8=FLI 9L@C;@E>C8JJC@=<J:@<E:<8E;I<J<8I:?:8DGLJ =FI8D@CC@FEGLI:?8J<GI@:< D@CC@FE>IFJJM8CL8K@FE N?@:?I<GI<J<EKJJK89@C@Q<;:8J?8E;#,:8G@K8C@Q8K@FEI8K<JF=8E; I<JG<:K@M<CP%E:FEALE:K@FEN@K?K?<KI8EJ8:K@FE $<8CK?G<8B<EK<I<; @EKF8

  6. Slide 6: Development Updates

    .$'(%&,-(,+ %E/<GK<D9<I $<8CK?G<8B8E;@KJAF@EKM<EKLI<G8IKE<I '@E>/KI<<K,IFG<IK@<J :FDD<E:<;:FEJKIL:K@FEFE8D9I@;><,8IB I@M< 8D@CC@FEC@=<J:@<E:<;<M<CFGD<EK GIFA<:KCF:8K<;@EK?<3<JK8D9I@;><JL9D8IB<KF=FJKFE ) 0FK8C@E>8GGIFO@D8K<CP JHL8I<=<<K K?<=@M< JKFIPC8JJC89FI8KFIP9L@C;@E>N@CC8CCFN$<8CK?G<8BKF:I<8K<8

  7. Slide 7: Company Information and Forward-Looking Statements

    '-, $, (# $<8CK?G<8B,IFG<IK@<J %E:@J8=LCCP@EK<>I8K<;I<8C<JK8K<@EM<JKD<EKKILJK.!%0 8E;/,:FDG8EP$<8CK?G<8BFNEJ8E;;<M<CFGJ?@>? HL8C@KPI<8C<JK8K<@EK?<K?I<<GI@M8K< G8P?<8CK?:8I< 8JJ<K :C8JJ<J F= (@=< /:@<E:< )<;@:8C +==@:< 8E; /<E@FI $FLJ@E> ;<J@>E<; KF GIFM@;< JK89@C@KP K?IFL>? K?< @E<M@K89C< @E;LJKIP :

  8. Slide 8: Consolidated Balance Sheets

    73>F:B73=(DAB7DF;7E !@5 A@EA>;63F763>3@57+:77FE %EK?FLJ8E;J <O:<GKJ?8I<8E;G<IJ?8I<;8K8 LE8L;@K<; X +7BF7?47D 757?47D EE7FE X X .<8C<JK8K< X X L@C;@E>J8E;@DGIFM<D<EKJ <M<CFGD<EK:FJKJ8E;:FEJKIL:K@FE@EGIF>I<JJ (8E; ::LDLC8K<;;<GI<:@8K@FE8E;8DFIK@Q8K@FE *<KI<8C<JK8K< *<K@EM<JKD<EK@E;@I<:K=@E8E:@E>C<8J<J

  9. Slide 9: Consolidated Statements of Operations

    73>F:B73=(DAB7DF;7E !@5 A@EA>;63F76+F3F7?7@FEA8'B7D3F;A@E %EK?FLJ8E;J <O:<GKG<IJ?8I<;8K8 LE8L;@K<; X X ,:D77%A@F:E@676+7BF7?47D &;@7%A@F:E@676+7BF7?47D N *7H7@G7E X X .<EK8C8E;I<C8K<;I<M<EL<J .<J@;<EK=<<J8E;J<IM@:<J %E:FD<=IFD;@I<:K=@E8E:@E>C<8J<J %EK<I<JK@E:FD< 0FK8CI<M<EL<J AEFE3@67JB7@E7E X X %EK

  10. Slide 10: Consolidated Statements of Operations (continued)

    73>F:B73=(DAB7DF;7E !@5 N G@6EDA?'B7D3F;A@E %EK?FLJ8E;J <O:<GKG<IJ?8I<;8K8 LE8L;@K<; X ,:D77%A@F:E@676 &;@7%A@F:E@676 "FI K?< E@E< DFEK?J <E;<; /<GK<D9<I I<C8K<J KF K?< +7BF7?47D +7BF7?47D >8@E FE :FEJFC@;8K@FE F= :FEK@EL@E> :8I< I<K@I<D<EK X :FDDLE@K@<J.J @EN?@:?N<8:HL@I<;IFFB;8C<J@EK<I<JK 8E;9<>8E

  11. Slide 11: Statements of Operations (continued)

    73>F:B73=(DAB7DF;7E !@5 X6<GEF76G@6EDA?'B7D3F;A@E X%EK?FLJ8E;J LE8L;@K<; X ,:D77%A@F:E@676+7BF7?47D &;@7%A@F:E@676+7BF7?47D X ""+8J;ALJK<;8GGC@:89C<KF:FDDFEJ?8I<J DFIK@Q8K@FEF=;<=<II<;:FDG<EJ8K@FE DFIK@Q8K@FEF=;<=<II<;=@E8E:@E>:FJKJ /KI8@>?K C@E<I<EKJ ""+:8G@K8C<OG<E;@KLI<J (<8J<I<JKIL:KLI<G8PD<EKJ

  12. Slide 12: Overview

    ,:7&G?47DE +M<IM@<N JF=8E;=FIK?<HL8IK<I8E;E@E<DFEK?J<E;<;/<GK<D9<I ;FCC8IJ JHL8I<=<<K 8E;J?8I<J@EK?FLJ8E;J <O:<GKG<IJ?8I<;8K8 ) 1, ;@3@5;3>%7FD;5E .<:FE:@C@8K@FEJ ;<=@E@K@FEJ 8E;@DGFIK8EK;@J:LJJ@FEJ @CLK<;<8IE@E>JG<I:FDDFEJ?8I< I<>8I;@E> K?< LJ<=LCE<JJ 8E; C@D@K8K@FEJ F= K?< EFE #, =@E8E:@8C D<8JLI<

  13. Slide 13: Portfolio Summary

    ,FIK=FC@F/LDD8IP JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J /7;9:F76 (DAB7DFK H7D397 (ADF8A>;A (ADF8A>;A (D;H3F7 AG@F 97 !@H7EF?7@F !@5A?7 (3K ('*,'$!'!&'% (DAB7DFK(ADF8A>;A /<E@FI?FLJ@E>KI@GC< E<K /$+, . . /$+, (@=<J:@<E:< /<E@FI?FLJ@E> )<;@:8CF==@:< KI@GC< E<K +K?<I $FJG@K8CJ8E;+K?<I 7H7

  14. Slide 14: Quarter NOI Summary

    -L8IK<I*+%/LDD8IP "FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ('*,'$!'&'!+-%%*1 (ADF8A>;A&'! ++&'! (ADF8A>;A (ADF8A>;A*73> 'B7D3F;@9 ++*73>EF3F7 ++'B7D3F;@9 EF3F7*7H7@G7E JB7@E7E (ADF8A>;A&'! *7H7@G7E JB7@E7E ++&'! /<E@FI?FLJ@E>KI@GC< E<K /$+, . * * * 0FK8C/<E@FI?FLJ@E> (@=<J:@<E:< )<;@:8CF==@:<

  15. Slide 15: Year to Date NOI Summary

    5<8I 0F 8K<*+%/LDD8IP "FIK?<E@E<DFEK?J<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ('*,'$!'&'!+-%%*1 (ADF8A>;A&'! ++&'! (ADF8A>;A*73> (ADF8A>;A EF3F7 'B7D3F;@9 ++*73>EF3F7 ++'B7D3F;@9 *7H7@G7E JB7@E7E (ADF8A>;A&'! *7H7@G7E JB7@E7E ++&'! /:A>>K 'I@76 /<E@FI?FLJ@E>KI@GC< E<K /$+, . * * * 0FK8C/<E@FI?FLJ@E> (@=<J

  16. Slide 16: Property Count Reconciliations

    ,IFG<IKPFLEK.<:FE:@C@8K@FEJ JF=/<GK<D9<I (*'(*,1'-&,*'&!$!,!'& +7@;AD AGE;@9 $;87 %76;53> ,D;B>7 @7F + '( * +5;7@57 '88;57 'F:7D ,AF3> (D;AD)G3DF7D,AF3>(DAB7DFKAG@F :HL@J@K@FEJ W W W W W JJ<KJJFC; W W W *<N <M<CFGD<EKJ W W W W W GDD7@F)G3DF7D,AF3>(DAB7DFKAG@F :HL@J@K@FEJ W W W JJ<KJ@E <M<CFGD<EK W W

  17. Slide 17: Capitalization

    8G@K8C@Q8K@FE FCC8IJ8E;J?8I<J@EK?FLJ8E;J <O:<GKGI@:<G<IJ?8I<;8K8 ,',$(!,$!2,!'& +7BF7?47D +:3D7E .3>G7 ,AF3>.3>G7 FDDFEJKF:B*5/!,!' FEM<IK@9C<G8IKE<IJ?@G FNE.!%0 LE@KJ ,AF3>%3D=7FCG;FK FEJFC@;8K<; <9K ,AF3>%3D=7FCG;FK3@6A@EA>;63F7674F /?8I<F=LE:FEJFC@;8K<;&2;<9K ,AF3>%3D=7FCG;FK3@6@F7DBD;E774F '%%'&

  18. Slide 18: Indebtedness and Ratios

    %E;<9K<;E<JJ8E;.8K@FJ JF=/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ,%,-*!,!+&+ -$(*!&!($*(1%&,+%'*,!2,!'& +:3D7A8-@5A@EA>;63F76 +7@;AD-@E75GD76&AF7E %ADF939774F ".74F @F7DBD;E774F 3@=$' A??7D5;3> A@EA>;63F76 (3B7D ,7D?$A3@ ?AG@FE *3F7E ?AG@FE *3F7E 74F ?AG@FE *3F7E ?AG@FE *3F7E W W W W W W W W W W W W W W W W W

  19. Slide 19: Debt Maturities and Ratios

    %E;<9K<;E<JJ8E;.8K@FJ JF=/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ,+,*-,-* /7;9:F76H7D397 173DEFA 3>3@57 A8,AF3> *3F7E %3FGD;FK +75GD76 "@O<;I8K< "CF8K@E>I8K< A?4;@76 -@E75GD76 "@O<;I8K< "CF8K@E>I8K< A?4;@76 ,AF3> "@O<;I8K< "CF8K@E>I8K< A?4;@76 @J:FLEKJ GI<D@LDJ8E;;<9K:FJKJ E<K )FIK>8><;<9KFE8JJ<KJ?<C;=FIJ8C< @

  20. Slide 20: Investment Summary

    %EM<JKD<EK/LDD8IP "FIK?<K?I<<8E;E@E<DFEK?J<E;<;/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J !&.+,%&,+-%%*1 (DAB7DFK ,:D77%A@F:E@676 &;@7%A@F:E@676 %+ 3F7 3B35;FK AG@F (DAB7DFK,KB7 +7BF7?47D +7BF7?47D )-!+!,!'&+ . 28I@FLJ &8EL8IP 1E@KJ . W 0?<,FJK FJKFE ) GI@C /H"K (@=<J:@<E:< W &LJK@:<(8E< #I<<EM@CC< /

  21. Slide 21: Investment Summary (continued)

    %EM<JKD<EK/LDD8IP JF=8E;=FIK?<E@E<DFEK?J<E;<;/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J ++,+ $'*+$ (DAB7DFK (DA<75F76+3>7E (DAB7DFK,KB7 3B35;FK AG@F (D;57 /$+, 1E@KJ /<E@FI?FLJ@E>KI@GC< E<K 1E@KJ . 1E@KJ )<;@:8CF==@:< /H"K +K?<I <;J ,AF3> !+('+!,!'&+ (DAB7DFK +3>7E(D;57 ,D3;>;@93E: 3F7 3B35;FK AG@F (

  22. Slide 22: Developments

    <M<CFGD<EKJ JF=/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J .$'(%&,(*'",+!&(*'++ ,AF3> A8 5FG3> EF;?3F76 (DA<75F ,AF3> '55GB3@5K (DAB7DFK AEFFA ,AF3>3F 3B35;FK (DA<75F (DA<75F (DA<75F %+ AG@F !( A?B>7F7 A?B>7F;A@ +C F $73E76 +F3DF !@;F;3> +F34;>;L76 $;87+5;7@57 .@;><M@<N /8E @<>F - - - 0?</?FI<8K/@<II8

  23. Slide 23: Redevelopments and Land Held for Development

    .<;<M<CFGD<EKJ8E;(8E;$<C;=FI <M<CFGD<EK JF=/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J@E:CL;<J&2GIFA<:KJ8KJ?8I< *.$'(%&,(*'",+!&(*'++ !@5D7?7@F3>AEFE EF;?3F76 (DAB7DFK (DAB7DFK (>3576;@ AEFFA (DA<75F A?B>7F;A@ (DA<75F %+ ,KB7 AG@F +7DH;57 !( A?B>7F7 ,AF3> +F3DF 3F7 28I@FLJ/$+, 28I@FLJ /$+, W - - - - '

  24. Slide 24: Capital Expenditures

    8G@K8C!OG<E;@KLI<J "FIK?<K?I<<8E;E@E<DFEK?J<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GKG<ILE@KJHL8I<=FFK +7@;AD AGE;@9 $;87 %76;53> , !*)-*,* ,D;B>7 @7F + '( * +5;7@57 '88;57 'F:7D ,AF3> (ADF8A>;A3FE:3D7 .<:LII@E>:8G@K8C<OG<E;@KLI<J W W 0<E8EK@DGIFM<D<EKJ E;><E<I8K@FE W W W (<8J<:FDD@JJ@FEJ E;><E<I8K@FE

  25. Slide 25: Portfolio Diversification

    ,FIK=FC@F @M<IJ@=@:8K@FE JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ('*,'$!'!&'%1%+ (DAB7DFK +7@;AD AGE;@9 %76;53> %+ AG@F ,D;B>7 @7F + '( * $;87+5;7@57 '88;57 'F:7D ,AF3> A8,AF3> /8E"I8E:@J:F W W 8CC8J 04 W W /8E @<>F W W W FJKFE ) W W W $FLJKFE 04 W (FJE><C<J W W ,?@C8;<CG?@8 , W W W /<8

  26. Slide 26: Portfolio Diversification by Operator

    ,FIK=FC@F @M<IJ@=@:8K@FE JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J ('*,'$!'!&'%1'(*,'* ,&&, ,7@3@F D76;FJBAEGD7 'B7D3FADJBAEGD7 +7@;AD A8 A8 (DAB7DFK AGE;@9 $;87 %76;53> (ADF8A>;A (DAB7DFK (ADF8A>;A 'B7D3FAD ,7@3@F AG@F ,D;B>7 @7F +5;7@57 '88;57 'F:7D ,AF3> !@5A?7 AG@F + '( * ,AF3> !@5A?7

  27. Slide 27: Expirations, Maturities and Purchase Options

    !OG@I8K@FEJ )8KLI@K@<J8E; ,LI:?8J<+GK@FEJ JF=/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J 0$-+(-* +&(*(1%&,'(,!'&+ @@G3>;L763E7*7@F +7@;AD AGE;@9 %76;53> !@F7D7EF 173D ,AF3> A8,AF3> ,D;B>7 @7F $;87+5;7@57 '88;57 'F:7D !@5A?7 W W W W W W W W W W W W W W W W W W W W W 0?<I<8=K<I W W ,AF3> 3<@>?K<;8M<I8>< D8KLI@KP@EP<

  28. Slide 28: Triple Net Master Lease Profile

    0I@GC< *<K)8JK<I(<8J<,IF=@C< A8 /7;9:F76 !O:CL;<JGIFG<IK@<J?<C;=FIJ8C<FIJFC; D8JK<IC<8J<JN@K?GIFG<IK@<J8:HL@I<;;LI@E> (ADF8A>;A3E: H7D397 K?< G<I@F; I<HL@I<; KF :8C:LC8K< " 8E; D8JK<I C<8J<J K?8K @E:CL;< E<NCP :FDGC<K<; &'!3@6 A8$73E7E %3FGD;FK;@ ;<M<CFGD<EKJ K?8K 8I< EFK /K89@C@Q<; ;;@K@FE8CCP <O:C

  29. Slide 29: Senior Housing Triple-Net

    /<E@FI$FLJ@E>0I@GC< E<K JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. !&.+,%&,+ +FD3;9:F >;@7 35;>;FK 35;>;FK (ADF8A>;A (ADF8A>;A *7@F '55GB3@5K *.('* !,*% !,* 'B7D3FAD !@H7EF?7@F 3E:&'! 3>3@57 AG@F -@;FE ,D;B>7 &7F IFFB;8C</<E@FI(@M@E> O O <>@J(@M@E> W * * * * $8I9FI.<K@I<D<EKJJ

  30. Slide 30: Senior Housing Triple-Net Same-Store

    /<E@FI$FLJ@E>0I@GC< E<K *<N/LGGCP JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J &/+-(($1&$1+!+ +7@;AD AGE;@9,D;B>7 @7F(ADF8A>;A %;>7*36;GE (ADF8A>;A3E: 173D A8,D;B>7 (DAB7DF;7E &'!JBAE76 (ABG>3F;A@ %76;3@ %76;3@ (ADF8A>;A @7F(ADF8A>;A -@;FE-@67D FA&7I DAIF: (7@7FD3F;A@ AGE7:A>6 A?7 -@7?B>AK %

  31. Slide 31: SHOP

    /$+, JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. !&.+,%&,+ (DAB7DFK (ADF8A>;A (ADF8A>;A3E: *.('* AG@F !@H7EF?7@F &'! -@;FE '55GB3@5K + '( 'B7D3FAD +8BDFEK/<E@FI(@M@E> /LEI@J</<E@FI(@M@E> * * IFFB;8C</<E@FI(@M@E> KI@8/<E@FI(@M@E> * * .<D8@E@E> ,AF3> ,',$+ '(('*,'$!' ) ) ) ) ) ,I

  32. Slide 32: SHOP Operating Trends

    /$+, )/ JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. '(*,!&('*,'$!'%,*!+ -@;FE *.('*+ '( A8+ '( (ADF8A>;A (ADF8A>;A (ADF8A>;A '55GB3@5K %+ !@H7EF?7@F 3E:&'! 3E:&'! $ !$ $ !$ /8E"I8E:@J:F W W (FJE><C<J W W $FLJKFE 04 *<N5FIB *5 W * * * /8:I8D<EKF W W ?@:8>F %( * * * 8CC8J 04 W '@

  33. Slide 33: Same-Store

    /$+, /8D< /KFI< FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. +7CG7@F;3> 173D 'H7D ) ) ) ) ) DAIF: 173DDAIF: ,IFG<IKP:FLEK W W ,FIK=FC@F%EM<JKD<EK 1E@KJ W W +::LG8E:P 9GJ 9GJ .!2,+./$+, ,FIK=FC@F.<8C!JK8K<.<M<EL<J ,FIK=FC@F+G<I8K@E>!OG<EJ<J9<=FI<D8E8><D<EK=<< )8E8><D<EK"<< (ADF8A>;A&'! ,FIK=FC@F8J?.<8C!JK8K<.<M<EL

  34. Slide 34: Non Same-Store

    /$+, *FE /8D< /KFI< FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. ) ) ) ) (DAB7DFK (ADF8A>;A (DAB7DFK (ADF8A>;A (DAB7DFK (ADF8A>;A (DAB7DFK (ADF8A>;A AG@F 3E:&'! AG@F 3E:&'! AG@F 3E:&'! AG@F 3E:&'! /8D< /KFI< /<>D<EK:FEM<IJ@FEJ :HL@J@K@FEJ JJ<KJ@E.<;<M<CFGD<EK.<;<M<CFGD<EK:FDGC<K<;9LKEFK /K89@C@Q<; JJ<KJ@E <M<CFGD

  35. Slide 35: New Supply

    /$+, *<N/LGGCP JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J &/+-(($1&$1+!+ + '( %;>7*36;GE A8 173D + '( (DAB7DF;7E (ADF8A>;A3E:&'! (ABG>3F;A@ %76;3@ (ADF8A>;A (ADF8A>;A -@;FE-@67D JBAE76FA&7I DAIF: (7@7FD3F;A@ AGE7:A>6 %76;3@ -@7?B>AK %+ -@;FE 3E:&'! 3E:&'! A@EFDG5F;A@ +GBB>K *3F7 !@5A?7 A?7

  36. Slide 36: Pro Forma Senior Housing

    ,IF"FID8/<E@FI$FLJ@E> JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. %E 8::FI;8E:< N@K? K?< FDG8EPJ GFC@:P 8E; @E;LJKIP GI8:K@:< GIFG<IK@<J :C8JJ@=@<; 8J ?<C; =FI J8C< 8I< <O:CL;<; =IFD /8D< /KFI< I<JLCKJ 8E; B<P D<KI@:J K?IFL>?FLK K?@J JLGGC<D<EK0?<FDG8EPJ;<:@J@FEKFJL9JK8EK@8CCPI

  37. Slide 37: CCRC Portfolio

    . JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J <O:<GK.!2,+. * (ADF8A>;A*73> (ADF8A>;A (DAB7DFK (ADF8A>;A EF3F7*7H7@G7E &* (ADF8A>;A 6<GEF76 '55GB3@5K *.('* &*3E: AG@F !@H7EF?7@F 7J5>G6;@9&*+ ?ADF;L3F;A@ 3E:'B7J &'! -@;FE * A>>75F;A@E 'B7D3FAD (@=<8I</<IM@:<J /LEI@J</<E@FI(@M@E> IFFB;8C</<E@F

  38. Slide 38: Life Science

    (@=</:@<E:< JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J !&.+,%&,+ (DAB7DFK (ADF8A>;A (ADF8A>;A3E: +CG3D7 '55GB3@5K %+ AG@F !@H7EF?7@F &'! 77F /8E"I8E:@J:F /8E @<>F FJKFE ) .<D8@E@E> +% +,'* ) ) ) ) ) ,IFG<IKPFLEK ,FIK=FC@F%EM<JKD<EK /HL8I<"<<K +::LG8E:P ,FIK=FC@F.<8C!JK8K<.<M<E

  39. Slide 39: Life Science Same-Store and Tenants

    (@=</:@<E:< JF=/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J +$,$+0(!*,!'&,&0,1*+ ,AF3> +3@D3@5;E5A +3@;79A AEFA@ *7?3;@;@9 $73E76 +CG3D7 @@G3>;L76 +CG3D7 @@G3>;L76 +CG3D7 @@G3>;L76 +CG3D7 @@G3>;L76 +CG3D7 @@G3>;L76 173D 77F 3E7*7@F 77F 3E7*7@F 77F 3E7*7@F 77F 3E7*7@F 77F 3E7*7@F W W W W W W W W W W W W

  40. Slide 40: Life Science Square Feet and Leasing

    (@=</:@<E:< /HL8I<=<<K@EK?FLJ8E;J $+!&,!.!,1 @@G3>;L76 ,7@3@F ,D3;>;@9,I7>H7 $73E76+CG3D7 3E7*7@F :3@97;@ !?BDAH7?7@FE $73E;@9AEFE H7D397$73E7 %A@F:*7F7@F;A@ 77F (7D+C F 3E:*7@FE B7D+C F B7D+C F ,7D?%A@F:E *3F7 $73E76+CG3D777F3EA8"G@7 .<;<M<CFGD<EKJGC8:<;@EJ<IM@:< ,IFG<IK@<JGC8:<;@EKFI<;<M<CFGD<EK !

  41. Slide 41: Medical Office

    )<;@:8C+==@:< JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J ('*,'$!'1%*#, +CG3D777F '@ 53?BGE '88 53?BGE ,AF3> (DAB7DFK (ADF8A>;A (ADF8A>;A '55GB3@5K %+ AG@F !@H7EF?7@F 3E:&'! %G>F; F7@3@F +;@9>7 F7@3@F %G>F; F7@3@F +;@9>7 F7@3@F %G>F; F7@3@F +;@9>7 F7@3@F A8,AF3> 8CC8J 04 $FLJKF

  42. Slide 42: Medical Office Summary and Health Systems

    )<;@:8C+==@:< JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I JHL8I<=<<K@EK?FLJ8E;J +)-*,1 $, +1+,% +CG3D777F ;D75F>K$73E764K 73>F:+KEF7? 73>F: +KEF7? D76;F A8@@G3>;L76 73>F:+KEF7? *3@= *3F;@9 '@ 3?BGE 6<357@F @5:AD76 '88 3?BGE ,AF3> A8,AF3> +CG3D777F 3E7*7@F $ 8 W )<DFI@8C$<ID8EE$<8CK?/PJK<D W W FDDLE@KP$<8CK?/P

  43. Slide 43: Medical Office Same-Store

    )<;@:8C+==@:< JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ8E;JHL8I<=<<K@EK?FLJ8E;J +$,$+0(!*,!'&,&0,1*+ ,AF3> '@ 3?BGE '88 3?BGE $73E76 @@G3>;L76 @@G3>;L76 @@G3>;L76 173D +CG3D777F 3E7*7@F +CG3D777F 3E7*7@F +CG3D777F 3E7*7@F 0?<I<8=K<I +% +,'* ) ) ) ) ) ,IFG<IKPFLEK ,FIK=FC@F%EM<JKD<EK /HL8I<"<<K +::LG

  44. Slide 44: Other (Wholly Owned)

    +K?<I 3?FCCP FNE<; JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J $+(*'(*,!+ 35;>;FK 35;>;FK (DAB7DFK (ADF8A>;A (ADF8A>;A '55GB3@5K !,*% !,* ,KB7 'B7D3FAD AG@F !@H7EF?7@F 3E:&'! 76E $FJG@K8CJ O O +K?<I@EM<JKD<EKJ W W * * * ,AF3> ,!&.+,%&,+ /7;9:F76 H7D397 !@F7D7EF %3FGD;FK;@ !@H7EF?7@F !@5A?7

  45. Slide 45: Outlook: Additional Items

    +LKCFFB;;@K@FE8C%K<DJ ,IFA<:K<;=LCCP<8I ;FCC8IJ@ED@CC@FEJ <O:<GKG<IJ?8I<8DFLEKJ ,C<8J<EFK<K?8KK?<=@>LI<JGIFM@;<;FEK?<J<G8><J;FEFKI<GI<J<EK>L@;8E:< G>>173D G>>173D 'GF>AA= 'GF>AA= G9GEF &AH7?47D &7F;@5A?7 '3@6'3E6<GEF76B7D+:3D7 ;H;67@6 @CLK<;<8IE@E>JG<I:FDDFEJ?8I< 3@K?;I8NE 3@K?;I8NE +E*FM<D9<I K?<F8

  46. Slide 46: Outlook: Additional Items

    +LKCFFB;;@K@FE8C%K<DJ FCC8IJ@ED@CC@FEJ <O:<GKG<IJ?8I<;8K8 'B7DE:3D7;?B35FE8AD%3K G9GEF3@6&AH7?47D#@AI@!F7?E %76;53>'88;57 $;87+5;7@573@6'@9A;@9*7@FA>>75F34;>;FKEE7EE?7@F'GF>AA=E3D7D7>3F;H7FAAGD 74DG3DKG;63@57A8 B7DE:3D73FF:7?;6BA;@F I:;5:I3E8AD?3>>KI;F:6D3I@;@%3D5: #@AI@!F7?E %3K'GF>AA= G9GEF'GF>AA=

  47. Slide 47: Outlook: Additional Items

    FCC8IJ@ED@CC@FEJ +LKCFFB;;@K@FE8C%K<DJ ,C<8J<EFK<K?8KK?<=@>LI<JGIFM@;<;FEK?<J<G8><J;FEFKI<GI<J<EK>L@;8E:< +AGD57E-E7E-B63F7 ,D3@E35F;A@6<GEF?7@FE+;@57$3EF)G3DF7D >AE76 ,D3@E35F;A@ G9GEF 'GF>AA= &7I5CG;E;F;A@E &AH7?47D 'GF>AA= !HL@KP=FIN8I;J W W @JGFJ@K@FEJ W JJLD<;;<9K W W .<MFCM<I;I8NG8P;FNE ,AF3>+

  48. Slide 48: Glossary

    #CFJJ8IP ;ALJK<;"@O<;?8I><FM<I8>< FEJFC@;8K<;/<:LI<; <9K ;ALJK<;!%0 I<;@M@;<;9P"@O<;?8I><J;ALJK<;"@O<;?8I><FM<I8><@J8JLGGC<D<EK8C )FIK>8>< 8E; FK?<I ;<9K J<:LI<; 9P I<8C <JK8K< 8J I<GFIK<; @E FLI :FEJFC@;8K<; =@E8E:@8C D<8JLI< F= C@HL@;@KP 8E; FLI 89@C@KP KF D<<K @EK<I<JK G8PD<EKJ FE FLI FLKJK8E;@E>

  49. Slide 49: Glossary

    #CFJJ8IP !EK<IGI@J</<:LI<; <9K "@O<;?8I><J FEJFC@;8K<;/<:LI<; <9KGCLJFLIGIFI8K8J?8I<F=DFIK>8><;<9K=IFDFLILE:FEJFC@;8K<; 0FK8C @EK<I<JK <OG<EJ< GCLJ :8G@K8C@Q<; @EK<I<JK GCLJ GI<=<II<; JKF:B ;@M@;<E;J @= 8GGC@:89C< &2J!EK<IGI@J</<:LI<; <9K@J8JLGGC<D<EK8CD<8JLI<F=FLI=@E8E:@8CGFJ@K@FE N?@:?<E89C<J "@O<

  50. Slide 50: Glossary

    #CFJJ8IP *<K <9KKF;ALJK<;!%0 I< ,FIK=FC@F%E:FD< *<K <9K;@M@;<;9P;ALJK<;!%0 I<@J8JLGGC<D<EK8CD<8JLI<F=FLI89@C@KPKF;<:I<8J<FLI 8J?*+%GCLJ@EK<I<JK@E:FD<GCLJFLIGIFI8K8J?8I<F=8J?*+%=IFDFLILE:FEJFC@;8K<;&2J ;<9K <:8LJ< N< D8P EFK 9< 89C< KF LJ< FLI :8J? KF I<;L:< FLI ;<9K FE 8 ;FCC8I =FI ;FCC8I C<JJEFE:FE

  51. Slide 51: Glossary

    #CFJJ8IP .!2,+.0I@GC< E<K /?8I<F=FEJFC@;8K<;&F@EK2<EKLI<J 0?< DFEK?8M<I8><=8:@C@KPI<M<EL<G<IF::LG@<;LE@K FE<HL8IK<I@E8II<8IJ=IFDK?<G<I@F; *FE:FEKIFCC@E> @EK<I<JKJ GIF I8K8 J?8I< @E=FID8K@FE @J GI<G8I<; 9P 8GGCP@E> EFE:FEKIFCC@E> GI<J<EK<; "8:@C@KP I<M<EL< :FEJ@JKJ GI@D8I@CP F= I<J@;<EK I<EKJ ><E<I8K

  52. Slide 52: Debt Ratios

    ;ALJK<;!%0 I<8E;;ALJK<; <9K.8K@FJ "@O<;?8I><FM<I8>< FCC8IJ@EK?FLJ8E;J &,!&'%,'"-+,!,D7 ,:D77%A@F:E@676 +7BF7?47D &7F;@5A?7>AEE %EK<I<JK<OG<EJ< %E:FD<K8O<OG<EJ<9<E<=@K <GI<:@8K@FE8E;8DFIK@Q8K@FE +K?<I;<GI<:@8K@FE8E;8DFIK@Q8K@FE (FJJ>8@E FEJ8C<JF=I<8C<JK8K< (FJJ>8@E LGFE:?8E><F=:FEKIFC %DG8@ID<EKJI<:F

  53. Slide 53: Debt Ratios

    <9K.8K@FJ JF=8E;=FIK?<HL8IK<I<E;<;/<GK<D9<I ;FCC8IJ@EK?FLJ8E;J &,*(*!+,&&,, +7BF7?47D 8EBC@E<F=:I<;@K8E;:FDD<I:@8CG8G<I %E:CL;<JDFIK>8><;<9KF=D@CC@FEFE8JJ<KJ?<C;=FI W J8C<K?8KD8KLI<J@E8E; 0<IDCF8E .<GI<J<EKJK?<:LII<EKHL8IK<I;ALJK<;!% 0I< /<E@FILEJ<:LI<;EFK<J DLCK@GC@<;9P8=8:KFIF==FLI )FIK>8><;<9K A@

  54. Slide 54: Information

    '%(&1 %E=FID8K@FE +. +" %.!0+./ *!& *,/*! , .! &*1 ?8@ID8EF=K?<F8I; $<8CK?G<8B,IFG<IK@<J %E: "FID<I2@:<?8@ID8E8E;?@<=!O<:LK@M<+==@:<I "FID<I#<E<I8CFLEJ<C '@D:F.<8CKPFIGFI8K@FE 1//<:LI@K@<J8E;!O:?8E><FDD@JJ@FE $1! #&&* , '%+% *2' ,I<J@;<EK8E;?@<=!O<:LK@M<+==@:<I ?@<=!O<:LK@M<+==@:<I $<8CK?G<8B,IFG<IK

  55. Slide 55: Doolingbrook Medical Office

    FC@E>9IFFB)<;@:8C+==@:< FC@E>9IFFB %( .<KLIEKF0+ .<KLIEKF0+

  56. Slide 56: Forward-Looking Statements and Risk Factors

    )<;@:8C@KP$FJG@K8C "FIN8I; (FFB@E>/K8K<D<EKJ 3>>3E ,0 .@JB"8:KFIJ /K8K<D<EKJ :FEK8@E<; @E K?@J JLGGC<D<EK8C I<GFIK N?@:? 8I< EFK ?@JKFI@:8C =8:KJ 8I< =FIN8I; CFFB@E> JK8K<D<EKJN@K?@EK?<D<8E@E>F=/<:K@FEF=K?</<:LI@K@<J:KF= 8J8D<E;<; 8E;/<:K@FE!F= K?</<:LI@K@<J!O:?8E><:KF= 8J8D<E;<;"FIN8I; CFFB@E>JK8K<

  57. Slide 57: Forward-Looking Statements and Risk Factors (concluded)

    "FIN8I; (FFB@E>/K8K<D<EKJ )<;@:8C,C8Q8 &3E:H;>>7 ,& .@JB"8:KFIJ:FE:CL;<; 8E; @KJ I<C@8E:< FE @KJ G8IKE<IJR =@E8E:@8C :FE;@K@FE 8E; :FEK@EL<; :FFG<I8K@FE :FDG<K@K@FE =FI K?< 8:HL@J@K@FE 8E; =@E8E:@E> F= JL@K89C< ?<8CK?:8I< GIFG<IK@<J 8J N<CC 8J :FDG<K@K@FE =FI K<E8EKJ 8E; FG<I8KFIJ @E:CL;@E> N@K? I<J

  58. Slide 58: Corporate Headquarters and Offices

    777777777777777777777777777777777777777777777777777777777 ADBAD3F7 ) 7@H7D ' /FLK?/PI8:LJ</KI<<K /L@K< <EM<I + 77777777777777777777777777777777777777777777777777777777 !DH;@7 )8@E/KI<<K /L@K< %IM@E< 7777777777777777777777777777777777777777777777777777777 &3E:H;>>7 ,& )<I@;@8EFLC<M8I; /L@K< "I8EBC@E

Healthpeak Properties — Q3 2020 Earnings Presentation on 6ix